Measurable Residual Disease (MRD) and Circulating Tumour Nucleotides (ct DNA) in cancer drug development

25-26 April 2022, Hybrid Workshop – Amsterdam, NL

Three previous Multi-Stakeholder Workshops organised by the CDDF on the same topic:

• Minimal Residual Disease: Endpoints in Clinical Trials, London, UK, May 13-14, 2014
• Minimal Residual Disease (MM), London, UK, October 18-19, 2017
• Minimal Residual Disease (AML/CLL), London, UK, November 8-9, 2018

WORKSHOP MATERIAL